Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares OutstandingWages, Salaries and Other
Ratios

Rhythm Pharmaceuticals (RYTM) Accumulated Depreciation & Amortization (2016 - 2024)

Historic Accumulated Depreciation & Amortization for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Q4 2024 value amounting to $710000.0.

  • Rhythm Pharmaceuticals' Accumulated Depreciation & Amortization fell 2137.32% to $710000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $710000.0, marking a year-over-year decrease of 2137.32%. This contributed to the annual value of $710000.0 for FY2024, which is 2137.32% down from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Accumulated Depreciation & Amortization of $710000.0 as of Q4 2024, which was down 2137.32% from $903000.0 recorded in Q4 2023.
  • In the past 5 years, Rhythm Pharmaceuticals' Accumulated Depreciation & Amortization ranged from a high of $903000.0 in Q4 2023 and a low of $710000.0 during Q4 2024
  • Its 4-year average for Accumulated Depreciation & Amortization is $831250.0, with a median of $856000.0 in 2021.
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Accumulated Depreciation & Amortization skyrocketed by 980.39% in 2022 and then tumbled by 2137.32% in 2024.
  • Quarter analysis of 4 years shows Rhythm Pharmaceuticals' Accumulated Depreciation & Amortization stood at $816000.0 in 2021, then rose by 9.8% to $896000.0 in 2022, then rose by 0.78% to $903000.0 in 2023, then dropped by 21.37% to $710000.0 in 2024.
  • Its last three reported values are $710000.0 in Q4 2024, $903000.0 for Q4 2023, and $896000.0 during Q4 2022.